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Background: Neuropsychiatric lupus (NPSLE) refers to the neurological and psychiatric manifestations that are
commonly observed in patients with systemic lupus erythematosus (SLE). An important question regarding the
pathogenesis of NPSLE is whether the symptoms are caused primarily by CNS-intrinsic mechanisms or develop as
a consequence of systemic autoimmunity. Currently used spontaneous mouse models for SLE have already
contributed significantly to unraveling how systemic immunity affects the CNS. However, they are less suited
when interested in CNS primary mechanisms. In addition, none of these models are based on genes that are
associated with SLE. In this study, we evaluate the influence of A20, a well-known susceptibility locus for SLE, on
behavior and CNS-associated changes in inflammatory markers. Furthermore, given the importance of environ-
mental triggers for disease onset and progression, the influence of an acute immunological challenge was
evaluated.
Methods: Female and male A20 heterozygous mice (A20þ/) and wildtype littermates were tested in an extensive
behavioral battery. This was done at the age of 102weeks and 24  2 weeks to evaluate the impact of aging. To
investigate the contribution of an acute immunological challenge, LPS was injected intracerebroventricularly at
the age of 102weeks followed by behavioral analysis. Underlying molecular mechanisms were evaluated in gene
expression assays on hippocampus and cortex. White blood cell count and blood-brain barrier permeability were
analyzed to determine whether peripheral inflammation is a relevant factor.
Results: A20 heterozygosity predisposes to cognitive symptoms that were observed at the age of 10  2 weeks and
24  2 weeks. Young A20þ/ males and females showed a subtle cognitive phenotype (102weeks) with distinct
neuroinflammatory phenotypes. Aging was associated with clear neuroinflammation in female A20þ/ mice only.
The genetic predisposition in combination with an environmental stimulus exacerbates the behavioral impair-
ments related to anxiety, cognitive dysfunction and sensorimotor gating. This was predominantly observed in
females. Furthermore, signs of neuroinflammation were solely observed in female A20þ/ mice. All above ob-
servations were made in the absence of peripheral inflammation and of changes in blood-brain barrier perme-
ability, thus consistent with the CNS-primary hypothesis.
Conclusions: We show that A20 heterozygosity is a predisposing factor for NPSLE. Further mechanistic insight and
possible therapeutic interventions can be studied in this mouse model that recapitulates several key hallmarks of
the disease.1. Background
Systemic lupus erythematosus (SLE) is a chronic autoimmune(Z. Callaerts-Vegh), patrick.callae
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Table 1
Number of animals used for each behavioral phenotyping.
BASELINE (3m old) BASELINE (6m old) LPS
WT A20  CRE FLOX WT A20  WT A20 
♀ 9 11 9 10 16 14 6 10
♂ 12 7 7 8 10 11
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duction of autoantibodies that form immune complexes upon binding
these nucleus-associated antigens and trigger abnormal inflammatory
responses. Since any organ system can be affected, SLE is associated with
a striking heterogeneity of clinical presentations (Kaul et al., 2016).
Neuropsychiatric systemic lupus erythematosus (NPSLE) refers to
manifestations that involve the central and peripheral nervous system
(ACR, 1999). Symptoms associated with the central nervous system
(CNS) are more common and are subdivided in focal and diffuse (Hanly
et al., 2010). Focal symptoms, such as cerebrovascular disease and sei-
zures, are caused by vascular events that are often triggered by
anti-phospholipid autoantibodies (Love and Santoro, 1990). They are
associated with structural brain abnormalities and respond well to
therapy (Hanly, 2014). Diffuse symptoms remain poorly understood but
are believed to be caused by neuroinflammatory mechanisms (Gelb et al.,
2018; Schwartz et al., 2019). Diffuse symptoms include depression,
anxiety and mood disorders, psychosis, acute confusional state and
cognitive impairment, and are not associated with structural brain ab-
normalities (ACR, 1999; Jeltsch-David and Muller, 2014).
The etiology of neuropsychiatric symptoms in lupus patients remains
unresolved (Bortoluzzi et al., 2018). In humans, neuropsychiatric
symptoms can be observed before or at the time of SLE diagnosis, indi-
cating that they can appear in absence of peripheral organ damage
(Hanly et al., 2007; Petri et al., 2010; van Dam et al., 1994). Furthermore,
it is repeatedly observed that symptoms arise independent from systemic
disease activity as measured by clinical and laboratory analysis
(Magro-Checa et al., 2019; Shimojima et al., 2005). This evidence sup-
ports the ‘CNS primary hypothesis’, where neuropsychiatric symptoms
are induced by CNS intrinsic mechanisms. On the other hand, neuro-
psychiatric symptoms can also arise as a secondary consequence of sys-
temic disease activity and they can be triggered by therapy, infections
and metabolic disorders. The latter is referred to as the ‘CNS secondary
hypothesis’. Research using mouse models of NPSLE has provided sup-
portive evidence for both hypotheses (Bendorius et al., 2018; Stock et al.,
2015; Wen et al., 2016). Most spontaneous mouse models for SLE are
characterized by key clinical manifestations associated with the auto-
immune character of the disorder and allow to study how systemic im-
munity is influencing the CNS. However, these models are less
appropriate to analyze how CNS intrinsic mechanisms contribute to the
etiology of NPSLE. A further important drawback of these spontaneous
mouse models for lupus is that none of them carry mutations in genes that
are associated with SLE (Schwartz et al., 2019).
TNFAIP3 (tumor necrosis factor alpha induced protein 3) is a well-
known susceptibility locus for SLE and recently, a mutation was discov-
ered in a patient with NPSLE (Duan et al., 2019; Ma and Malynn, 2012).
TNFAIP3 encodes the ubiquitin-editing enzyme A20, a strong negative
regulator of the family of nuclear factor-kappa B (NF-κB) transcription
factors and a prominent cytoprotective protein (Adrianto et al., 2011;
Graham et al., 2008; Musone et al., 2008; S. Wang et al., 2013). The
NF-κB pathway regulates the expression of a large number of genes that
are critical for innate and adaptive immunity. This signaling pathway
needs to be tightly regulated as uncontrolled activity is associated with
several autoimmune disorders, chronic inflammatory diseases, neuro-
logical disorders and cancer (Zhang et al., 2017). Consistent with this
notion, it has been shown in vitro for a pair of SLE-associated functional
variants (TT > A enhancer) that they significantly reduce the expression
of A20 which is associated with an increased activity of the NF-κB
pathway (Wang et al., 2016).
The function of A20 is complex and still incompletely understood.
Originally, A20 was thought to control NF-κB activity in a dual manner.
Biochemical assays identified two motifs in the A20 protein that have
ubiquitinating and de-ubiquitinating activity (Evans et al., 2004; Wertz
et al., 2004). The ovarian tumor domain (OTU) located N-terminally
harbors deubiquitinating activity resulting in the destabilization of
protein-protein interactions (Evans et al., 2004; Wertz et al., 2004). On
the other hand, Znf4, one of the seven zinc finger motifs located at the2
C-terminus of the A20 protein, was shown to have ubiquitin ligase ac-
tivity that targets proteins for proteasomal degradation (Bosanac et al.,
2010; Wertz et al., 2004). In vivo evaluation of protein variants in which
the enzymatic function of either the OTU domain and ZnF4 was inacti-
vated by mutation, questions the importance of these findings since the
phenotypes observed in these mice did not resemble the phenotype
observed upon A20 deficiency (De et al., 2014; Lu et al., 2013; Wertz
et al., 2015). Currently, it is believed that A20 uses mainly non-catalytic
ubiquitin binding mechanisms to control NF-κB activity (Skaug et al.,
2011; Verhelst et al., 2012; Wertz et al., 2015).
The essential anti-inflammatory function of A20 was demonstrated in
a knockout mouse model, where animals died prematurely due to severe
organ inflammation (Lee et al., 2000). Furthermore, A20 knockout and
heterozygous mouse models develop spontaneous neuroinflammation
without changes to blood brain barrier (BBB) permeability (Guedes et al.,
2014). The latter already indicates that the contribution of systemic
immunity to the development of neuroinflammation is limited. Conse-
quently, A20 heterozygous mice could represent a good model to
disentangle the role of systemic immune response from CNS intrinsic
mechanisms in the development of neuropsychiatric symptoms.
In this study, the behavioral phenotype of A20 heterozygous mice was
evaluated to test the ‘CNS primary hypothesis’. This was done in young (3
months old) and more mature (6 months old) mice to evaluate the impact
of aging. The latter is of importance since the peak age of incidence for
SLE in humans ranges from 30 to 70 years old (Rees et al., 2017).
Furthermore, since it is known that genetic as well as environmental
factors contribute to the pathogenesis of NPSLE, the relative impact of
A20 heterozygosity in the context of an acute immunological challenge
was evaluated. This study identifies A20 heterozygosity as a predisposing
factor and provides more insight in the mechanisms by which genetic
predisposition can contribute to the establishment of neuropsychiatric




The conditional A20 allele was created by targeting exons 4 and 5 as
described (Vereecke et al., 2010). A20 heterozygous knockout (A20þ/)
mice were generated by breeding A20 heterozygous floxed (A20þ/FL)
females with PGK-Cre transgenic male mice. This resulted in four
different genotypes: A20 heterozygous knockout (A20þ/), A20 hetero-
zygous floxed (A20þ/FL), PGK-Cre recombinase mice (PGK-Cre) and
wildtype (WT) mice (Table 1). All experiments were performed on mice
backcrossed into the C57Bl/6 background for at least 10 generations.
Sex-mixed groups of animals aged 8–12 weeks were used for behavioral
experiments on young mice (referred to as 3 months old) and mature
mice at the age of 24 2 weeks old (referred to as 6 months old). The test
battery evaluated motor, emotional, social, cognitive and disease-related
behavior. All experiments were conducted during the light phase of their
active cycle. For the LPS dose-response study, 8-weeks old C57Bl/6J
female mice were purchased from Elevage Janvier (Le-Genest Saint-Isle,
France). After determination of the optimal LPS dose, wildtype and
A20þ/ mice were injected with LPS at the age between 8 and 11 weeks
old (average age 9.5 weeks) and tested in a behavioral battery. This
behavioral battery focused specifically on motor function, emotional,
C. Daems et al. Brain, Behavior, & Immunity - Health 2 (2020) 100018cognitive and disease-related phenotypes. All animals were
group-housed under conventional laboratory conditions (12h light/dark,
22 C) with ad libitum access to food and water. All protocols and ex-
periments were approved by the KU Leuven Ethical Committee and in
accordance with the European Community Council Directive
2010/63/EU.
2.2. Behavioral test battery
General neuromotor assessment: Cage activity and neuromotor coordi-
nation were assessed by various tests including 23h spontaneous cage
activity, motor coordination and balance on the accelerating rotarod and
grip strength measurement. Detailed protocols are described in (D’Hooge
et al., 2005). 23h spontaneous cage activitywas measured using a lab-built
activity logger connected to three infrared photo beams. Mice were
individually placed in 20  30 cm2 transparent home cages and their
activity, measured by the number of beam crossings, was recorded over a
period of 23 h. Protocols regarding neuromotor coordination and grip
strength are described in Supplementary Methods.
Evaluation of exploratory, anxiety-related and social behavior: Explora-
tion in open field and on elevated plus maze (Supplementary Methods)
allows evaluation of anxiety-related behavior (Callaerts-Vegh et al.,
2006; D’Hooge et al., 2005). Before introducing the animals in the open
field arena (50  50 cm2), animals were habituated in the dark for 30
min. Exploration in the arena was measured for 11 min (including 1 min
habituation) using ANY-maze™ video tracking system software (Stoelt-
ing Co, IL, US). Total path length and the time spent in center and pe-
riphery were used as read-outs for exploratory behavior and anxiolysis,
respectively. Assessment of social behavior was done using sociability
and preference for social novelty (see Supplementary Methods) (Nadler
et al., 2004; Naert et al., 2011a).
Cognitive assessment: Spatial learning, memory and cognitive flexi-
bility were evaluated in the hidden-platform Morris water maze using
acquisition and reversal learning protocols (Callaerts-Vegh et al., 2012;
D’Hooge et al., 2001; Stewart and Morris, 1993). A circular pool
(diameter 150 cm) was filled with opacified water (nontoxic white paint)
and maintained around 26  1 C. The platform (diameter 15 cm) was
hidden 1 cm underneath the water surface. Its location was the same
throughout the 10 days of spatial acquisition, but moved to the opposite
quadrant during the additional 5 days of reversal learning. Probe trials
(platform was removed from the pool) were performed on day 6 and 11
of acquisition and at the end of reversal learning. Animals were trained
daily in four sequential sessions (15–30 min interval) starting from each
of the four starting positions. Animals that were not able to find the
platform within 120 s, were gently guided to the platform where they
remained for 15 s before being transferred to their home cage. EthoVision
video tracking equipment and software (Noldus, Wageningen, The
Netherlands) were used to quantify and extract swim path parameters.
The search strategy of each mouse during the probe trials was scored and
classified using a 3-class scoring method (Brody and Holtzman, 2006;
Callaerts-Vegh et al., 2012; Lo et al., 2013). The 3-class scoring method
distinguishes spatial memory-dependent strategies and less proficient, or
non-spatial and repetitive strategies. Protocols regarding T-maze, Y-maze
and cued- and context-dependent fear conditioning can be found in
Supplementary Methods (Paradee et al., 1999).
Disease-associated phenotypes: Startle reactivity and prepulse inhibi-
tion (PPI) of the acoustic startle reflex were measured using a Med As-
sociates acoustic startle box (St. Albans, VT, USA) as described previously
(Naert et al., 2011b). Mice were restrained in a cubicle (ENV-406SM-8)
that was mounted on a motion-sensitive platform located inside a
sound-attenuating box and connected to Med Associates Startle Reflex
software (v5.01). After a habituation period of 5 min, two startle pulse
trial blocks were presented. The first phase consisted of five basic startle
pulses (115 dB). In the second phase startle pulses, prepulses (70, 75 or
80 dB) and prepulse-startle pulses were presented at random. Percentage
PPI (%PPI) was calculated according to the standard formula: %PPI¼ [1-3
(startle peak of prepulse-startle pulse)/(startle peak of startle pulse)] *
100. Depression-like behavior was analyzed using the forced swim test
protocol (Supplementary Methods).
2.3. LPS administration
Animals were anesthetized using Iso-Vet (1000 mg/g Isofluran,
Dechra Veterinary Products NV,Belgium) and placed in the robot ste-
reotactic frame (Neurostar, Germany). Mice were placed on a heat pad
(36 C) to prevent hypothermia, and eyes were protected using Lac-
rinorm (Bausch&Lomb Pharma, Belgium). Before the onset of surgery, a
local anesthetic, Xylocaine® (AstraZeneca, Belguim), was injected sub-
cutaneously at the location of the incision. LPS from Escherichia coli
0111:B4 (Sigma-Aldrich, US) was dissolved in saline (Braun Vet care,
Germany) to obtain the following concentrations: 10 ng/μl, 30 ng/μl,
100 ng/μl, 300 ng/μl and 1000 ng/μl. Bilateral intracerebroventricular
(icv) injections (total volume 1 μl) were performed using a 10 μl syringe
with a 26s gauge needle (Hamilton, Nevada US). Stereotactic injections
were done at a constant rate of 0.1 μl/min, using the following co-
ordinates (AP: 0.57 mm, Lat:1.18 mm, Z: 1.93 mm). After injection, the
needle remained in position for an additional 5 min and was slowly
retracted (100 μm per 30s) afterwards to avoid backflow. Intraperitoneal
injection using 0.3 mg/ml Vetergesic® (20%BW, Ecuphar®, Breda, The
Netherlands) was applied to limit postoperative pain and Triple anti-
biotic ointment (Walgreen Co, USA) was applied to prevent infections.
The weight of all animals was monitored over the course of the experi-
ment as an indicator for their general wellbeing.
2.4. Blood cell analysis and tissue isolation
Dolethal® (60 mg/kg, Vetequinol, Belgium) was injected intraperi-
toneally to deeply anesthetize the animals before blood collection and
consecutive isolation of brain tissue. Blood samples were obtained from
the retro-orbital sinus using Brand™ Micro-haematocrit capillary tubes
(Fisher Scientific). White blood cell count was measured at least 24h after
collection using the scil Vet ABC Plus™ (scil animal care company
GmbH). After blood collection, hippocampus and cortex were isolated on
ice and flash frozen for further gene expression analysis. At the time of
tissue isolation, the group of animals used had the following age: 3-
month old animals were approximately 19.5 weeks old, 6-month old
animals were 36.5 weeks old and the animals injected at the age of 3-
month old were approximately 14 weeks old.
2.5. Blood-brain barrier (BBB) permeability assay
To evaluate the permeability of the blood-brain barrier, fluorescein
(FITC) labeled dextran (3000 MW, ThermoFisher Scientific) was injected
intraperitoneally. The protocol was largely adopted from Devraj et al.
(2018). FITC-dextran was injected either in mice at the age of 6 months
or in 3 months old mice that received an LPS injection. After 5 min they
received a lethal dose of Dolethal® (60 mg/kg, Vetequinol, Belgium).
15–20 min after the intraperitoneal injection of FITC-dextran, the ani-
mals were perfused and serum as well as the hemicerebrum were
collected. Tissue was homogenized in 200 μl PBS and centrifuged at
15000 g, 4 C for 20 min. Afterwards the 50 μl of the supernatant and
serum (20 μl serumþ 30 μl PBS) were measured using Infinite® 200 PRO
(Tecan, Switserland). Raw fluorescence units were used to calculate the
permeability index as described (Devraj et al., 2018).
2.6. qPCR analysis
Total RNA from hippocampal tissue and cortex was isolated using TRI
reagent (Invitrogen). Reverse transcription on 1 μg RNA was performed
using SensiFAST™ cDNA Synthesis Kit (Bioline) according to manufac-
turers’ instructions. Primers were designed to span an exon-exon junction
and sequences are listed in (Table S1). qPCR was performed on a Viia 7
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detection (Bioline). Transcript levels were normalized to the geometric
means of the reference genes Pgk1 (phosphoglycerate kinase 1) and
Wdr33 (WD repeat domain 33). Candidate reference genes were obtained
using the RefGenes tool (Genevestigator®, Nebion) and validated against
commonly used reference genes. The geNorm algorithm (qbaseþ, Bio-
gazelle) was used to select two reference genes with the most stable
expression in the tissue of interest (Hellemans et al., 2007; Willems et al.,
2008). The comparative Ct method was used to calculate relative gene
expression (Schmittgen and Livak, 2008).
2.7. Statistical analysis
Results are expressed as mean  SEMs unless stated otherwise. To
analyze behavioral readouts, differences between mean values were
determined using t-test, one-way analysis of variance (ANOVA) and two-
way repeated measures analysis of variance (RM-ANOVA). Tukey tests
were used for post hoc analysis. Log transformation of the data and non-
parametric tests were performed when data did not meet the assumption
of normality. Analysis of qPCR results was done using unpaired t-tests for
pairwise comparisons or one-way ANOVA tests for multiple comparisons
using Tukey’s multiple comparisons post hoc. All statistical analyses were
performed using GraphPad Prism software and tests were performed
assuming a significance level of 0.05.
3. Results
3.1. A20 heterozygosity leads to subtle cognitive impairments
NPSLE is characterized by a diversity of psychiatric symptoms. To
identify the influence of A20 heterozygosity on behavioral phenotypes,
A20þ/ mice and wildtype control littermates were subjected to an
extensive behavioral battery to analyze motor function, emotional
function, social behavior, cognitive function and disease-related pheno-
types. A20 heterozygous floxed (A20þ/FL) and PGK-Cre littermates
served as additional controls in the behavioral battery. Since no behav-
ioral differences were found between A20þ/FL, PGK-Cre and wildtype
mice, further comparisons were limited to WT and A20þ/ mice
(Table S2).
For most behavioral assays, no phenotypic differences between A20þ/
 and WTmice were found (Table S3). Only a subtle cognitive defect was
detected in the Morris water maze (MWM) (Fig. 1). During the acquisi-
tion phase, overall performance of WT and A20þ/ mice was similar.
Only on the first two days of acquisition, thigmotaxis was increased in
A20þ/ mice compared to WT littermates (genotype x time: F27,585 ¼ 1.80,
P ¼ 0.008, Fig. 1B). A memory-related defect was found in the first probe
trial where wildtype animals spent significantly more time in the target
quadrant (T) over the other quadrants (quadrant preference: F3,198 ¼
27.07, P < 0.0001; Fig. 1C), whereas A20þ/ mice did not show this
preference. However, they did show a significant preference for the
target quadrant after ten days of training (quadrant preference: F3,198 ¼
134.8, P < 0.001; Fig. 1D). This indicates that A20þ/ mice need more
time to form a robust reference memory of the platform’s location. A
visual representation, plotting the time spent in the different quadrants
during the probe trials, confirms the preference for the target quadrant in
WT animals after 5 days of training (Fig. 1E). The performance during the
probe trials was further evaluated to identify the search strategies that
were used by each animal individually (Brody and Holtzman, 2006).
Spatial strategies are observed when spatial cues are used to swim
directly to the location of the platform, whereas non-spatial strategies do
not rely on cognitive abilities. The latter can be subdivided into
non-spatial and repetitive search strategies. Here, search strategies were
evaluated until the animal crossed the platform’s location for the first
time (Fig. 1F). No significant differences were found between A20þ/
andWTmice within the same probe trial, as well as between probe trial 1
and 2.4
A recent systematic review of epidemiological studies on SLE has
estimated the peak age of incidence for females between 30 and 70 years
old (Rees et al., 2017). Thus far, the animals used for behavioral char-
acterization were 3 months old, which corresponds to a human age of
approximately 20 years (Flurkey et al., 2007). Since the peak age of
incidence occurred mainly in middle-aged adults, we decided to evaluate
the cognitive behavior of female A20þ/ and WT littermates at the age of
6 months (30 years in humans) (Flurkey et al., 2007). Cognitive func-
tion was only evaluated in female A20þ/ mice because of the female
predominance that is observed in SLE (Table 1). During acquisition
learning in the Morris water maze experiment, similar learning curves for
both path length (Figs. S1–A) and time spent in periphery (Figs. S1–B)
were observed for female A20þ/ and WT littermates. The first probe
trial, conducted after five days of training, revealed that none of the
genotypes showed a significant preference for the target quadrant and
that they needed more training to form a robust memory of the platforms
location (Figs. S1–C). After ten days of training, all genotypes were
spending significantly more time in the target quadrant (Figs. S1–D).
Subsequently, we investigated cognitive flexibility by means of reversal
learning in which the platform is moved to the opposite quadrant. Over
the five days of training, a difference in mean distance to target was
observed between WT and A20þ/ mice (Fig. 2). On the first day of
reversal learning wildtype animals did not show a significant difference
in the distance towards the acquisition (acq) and reversal target (rev)
(time x target: F4, 96¼ 29.60, p< 0.0001; target: F4,96¼ 46.18, p< 0.0001;
post hoc day 1: t120 ¼ 2.15, p ¼ 0.15, Fig. 2A). In contrast, A20þ/ mice
were still swimming significantly closer to the acquisition target (time x
target: F4,88 ¼ 56.84, p< 0.0001; time: F1,22 ¼ 64.71, p< 0.0001; post hoc
day 1: t110 ¼ 3.61, p ¼ 0.002; Fig. 2B). This implies a difference in per-
formance on the first day of reversal learning. This day is of particular
interest as it gives an indication of how fast the animals are able to update
their initial swim strategy. Further evaluation of the mean distance to
target for A20þ/ and control littermates confirms the previously
observed difference in learning. Wildtype animals show a significant
preference for the new location of the platform at the fourth trial on the
first day of reversal learning (time x target: F3,72¼ 28.81, p< 0.0001, time:
F1,24 ¼ 9.47, p ¼ 0.005; post hoc trial 4: t23 ¼ 3.19, p ¼ 0.01; Fig. 2C),
which was not observed for A20þ/ (time x target: F3,66 ¼ 18.22, p <
0.0001; time: F1,22 ¼ 10.69, p ¼ 0.0035; post hoc trial 4: t21 ¼ 1.96, p ¼
0.24; Fig. 2D). After five days of reversal learning, a probe trial was
conducted during which both wildtype and A20þ/ mice showed a sig-
nificant preference for the target quadrant (Fig. 2E) and are swimming
significantly closer to the new location of the platform in comparison to
the previous location (Fig. 2F). Thus, A20þ/ females at the age of 6
months show a defect in reversal learning that corresponds to a deficit in
cognitive flexibility.
In summary, at the age of 3 months, A20þ/ animals show a subtle
cognitive impairment compared to control littermates. The impairment
includes the need for more time to form a robust reference memory. All
other behavioral tests showed similar behavior in A20þ/mice compared
to WT littermates. With age, female A20þ/ mice show a learning defect
in reversal learning and thus cognitive flexibility.
3.2. Immune challenge in A20þ/ mice results in more behavioral
phenotypes
The pathogenesis of neuropsychiatric lupus is characterized by a
complex interplay of genetic, hormonal and environmental factors. In
order to mimic the disease pathogenesis more closely, A20þ/ mice were
exposed to an immune challenge. Lipopolysaccharide (LPS), an endo-
toxin derived from the outer membrane of Gram-negative bacteria, is
known to be a powerful trigger of inflammation by activating the NF-κB
pathway (Bryant et al., 2010). To avoid systemic inflammation, intra-
cerebroventricular (ICV) injections were performed.
LPS concentration study: In the literature, a wide range of LPS doses are
used for ICV injections but a systematic analysis of optimal dosing is
Fig. 1. A subtle memory deficit was observed in A20 heterozygous mice in comparison to wildtype littermates.
(A) No difference in path length was observed between A20 heterozygous mice (A20þ/, white circles) and wildtype mice (WT; black circles) during acquisition; (B)
A20þ/ mice spent significantly more time in the periphery in comparison to WT littermates. This was most pronounced on the first and second day of acquisition; (C)
After five days of training, A20þ/ mice showed less preference for the target quadrant in comparison to the other three quadrants (T: Target, O: Opposite, A1:
Adjacent 1 and A2: Adjacent 2 quadrants); (D) Preference for the target quadrant after ten days of training is seen for both genotypes; (E) Visual representation of the
time spent in different quadrants for WT and A20þ/ mice during both probe trials; (F) Search strategies used during the acquisition probe trials by A20þ/ and WT
littermates. No significant differences were found between A20þ/ and WT littermates within as well as between probe trials. Data are represented as meanSEMs (A-
D) and as ratios (F). Statistical differences were determined using repeated-measures two-way ANOVA using Dunnett’s multiple comparisons test for post hoc analysis
(A-D) and Fisher’s exact test (F); (*P < 0.05, ****P < 0.0001).
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ranging from 10 ng/μl to 1000 ng/μl, in wildtype female mice (Fig. S2).
The effect of a single injection was followed over time (6h, 24h, 3d and
7d) and parameters related to neuroinflammation, peripheral inflam-
mation and the general wellbeing of mice were evaluated (Table S4).
Based on these results, 100 ng/μl LPS was selected for injection in A20þ/
 mice. This concentration was associated with a significant decrease in
weight for at least three days after surgery, limited signs of peripheral
inflammation and a strong pro-inflammatory response in the5
hippocampus that was counteracted by anti-inflammatory mediators.
The effect of 100 ng/μl ICV LPS in comparison to saline ICV injections
was evaluated in female A20þ/ mice prior to the behavioral analysis
(Fig. S3). A strong inflammatory response was observed in the animals
injected with LPS. This response was characterized by the upregulation of
pro-inflammatory cytokines (Tumor necrosis factor, Tnf 6h: t4 ¼ 3.81, P ¼
0.01; 24h: t4 ¼ 2.63, P ¼ 0.058; Interleukin 1b, Il1b 24h: t4 ¼ 2.81, P ¼
0.04), activation of microglia (Toll-like receptor 4, Tlr4 6h: t4 ¼ 5.89, P ¼
0.004), oxidative stress (NADPH oxidase 2, Nox2 6h: t4 ¼ 11.46, P ¼
Fig. 2. A20þ/ female mice show
cognitive flexibility deficits at the age of
6 months.
(A) Mean distance to the acquisition
(dark circles) and reversal (white circles)
platforms for wildtype animals during
reversal learning. On the first day, no
significant preference for either the new
nor the old location of the platform is
seen; (B) In contrast, A20þ/ mice are
swimming significantly closer to the old
location (acq, black squares) of the
platform; (C) Detailed analysis of the
first day of reversal learning, shows that
wildtype animals show a significant
preference for the new location of the
platform after four training sessions; (D)
whereas A20þ/ mice fail to do so. (E)
After five days of training, both WT and
A20þ/ mice show a significant prefer-
ence for the target quadrant and; (F) are
swimming significantly closer to the
reversal platform. All data are repre-
sented as meanSEMs and statistical
significance was determined by using
two-way repeated measures ANOVA (A-
E) or two-way ANOVA (F) using Sidak’s
multiple comparisons test as post hoc
analysis; (**P < 0.01, ***P < 0.001).
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Whereas the pro-inflammatory mediators were mainly upregulated for
the first 2 days, the anti-inflammatory cytokine Transforming Growth
Factor beta (Tgfb) was upregulated until 7 days after the injection (6h: t4
¼ 3.47, P¼ 0.02, 24h: t4¼ 4.32, P¼ 0.01, 3d: t4¼ 2.48, P¼ 0.06 and 7d:
t4 ¼ 5.20,P ¼ 0.006). Evaluating peripheral inflammation using white
blood cell markers showed no difference in absolute leukocyte levels in
comparison to saline injected A20þ/ female mice. This indicates that the
neuroinflammatory reaction occurred in absence of peripheral
inflammation.
Neuromotor behavior: Two days after surgery, spontaneous activity
levels over 23 h were measured in LPS injected wildtype and A20þ/
littermates (both sexes, see Table 1). In general, A20þ/ mice were
hypoactive. This effect was observed in both A20þ/ male and female
mice. However, the effect was more pronounced in female mice where a
significant decrease in overall spontaneous activity (genotype x time F14,
644 ¼ 2.57, P < 0.0001; time: F46,644 ¼ 18.17, P < 0.0001 and genotype:
F1,14 ¼ 5.81, P ¼ 0.03; Fig. 3A) and decreased activity during the dark
period (t14 ¼ 2.8, P ¼ 0.01; Fig. 3B) was observed. In males, only a
decrease in overall activity was observed (time: F46,828 ¼ 21.70, P <
0.0001; genotype x time F46,828 ¼ 1.39, P ¼ 0.045; Figs. S4–A) but no
difference was seen during the dark period (t18 ¼ 1.13; P ¼ 0.27,6
Figs. S4–B). Besides hypoactivity, a significant reduction in weight was
found specifically for female A20þ/ mice compared to WT mice. This
decrease was especially present on the second day after surgery (weight x
genotype: F7,89 ¼ 3.86, P ¼ 0.001 and weight: F7,89 ¼ 81.71, P < 0.0001;
Fig. S5). The hypoactivity that is especially present in A20þ/ female
mice, is probably influenced by general malaise due to the LPS injections.
The increased weight reduction in A20þ/ female mice suggests a
stronger impact from the acute injection compared to males.
Disease-associated behavior: The presence of an anxiety-like phenotype
was assessed one week after surgery using the open field experiment.
A20þ/ female mice showed increased anxiety-related behavior since
they spent less time in the center (Mann-Whitney U ¼ 8, n1 ¼ 6, n2 ¼ 10,
P ¼ 0.01; Fig. 3C) and more in the periphery (t14 ¼ 3.576, P ¼ 0.003;
Fig. 3D). No differences in exploratory behavior were observed, indi-
cating that the anxiety-related phenotype is not influenced by motor
impairment (Path length: Mann-Whitney U ¼ 22, n1 ¼ 59, n2 ¼ 77, P ¼
0.47, data not shown). This effect was only observed in female A20þ/
mice, as male A20þ/ mice did not show any difference in time spent in
the center (Mann-WhitneyU¼ 54, n1¼ 10, n2¼ 11, P¼ 0.97; Figs. S4–C)
or periphery (t19 ¼ 1.06, P ¼ 0.29; Figs. S4–D).
Startle reflex and prepulse inhibition to an acoustic startle were
measured approximately 26 days after LPS injection. The acoustic startle
Fig. 3. Behavioral phenotypes observed in A20þ/ female mice aggravate after immune challenge.
(A) Overall spontaneous activity and; (B) activity during the dark period of female A20þ/ mice are significantly lower in comparison to wildtype littermates; (C)
A20þ/ female mice display an anxiety-related phenotype as is evidenced from the open field experiment where they spent significantly less time in the center and; (D)
more time in the periphery in comparison to wildtype littermates; (E) A normal startle response was observed in both genotypes, however; (F) A20þ/ female animals
showed significantly higher startle reactivity when a prepulse was preceding the original startle tone. This is indicative for a sensorimotor gating impairment. Data are
represented as meanSEMs and statistical differences were determined using repeated-measures two-way ANOVA using Dunnett’s multiple comparisons test for post
hoc analysis (A, F), unpaired t-test (B, C, E), Mann Whitney test (D) and two-way ANOVA using Sidak’s multiple comparisons test for post hoc analysis (F); (*P < 0.05,
**P < 0.01).
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motor response induced by the startle tone can be modulated when an-
imals are pre-exposed to a mild stimulus or prepulse. This process is
called prepulse inhibition (PPI) and is a measure of sensorimotor gating.
LPS injected A20þ/ female mice showed a normal startle response
(Fig. 3E) but a disrupted prepulse inhibition (genotype: F1,42 ¼ 8.31, P ¼
0.006; Fig. 3F). This indicates that female mice have a deficit in their
sensorimotor gating, meaning that they are less capable of processing and
integrating sensory and cognitive/motor information. Again, this effect
was found to be female-specific, since no differences in startle reflex (t19
¼ 0.57, P ¼ 0.57; Figs. S4–E) and prepulse inhibition (genotype: F1,56 ¼
0.73; P ¼ 0.39; Figs. S4–F) were found between A20þ/ and WT male
littermates. Furthermore, none of the above described behavioral defi-
cits, related to activity, anxiety and prepulse inhibition, were found to
show any difference between females A20þ/ and WT littermates at the
age of 3months, which indicates that they were triggered by the presence
of an immune challenge (Fig. S6).
Cognitive behavior: The Morris water maze experiment was started ten
days after the LPS challenge to evaluate spatial learning and memory. In
the second phase of acquisition (days 6–10), a subtle learning defect was
observed in A20þ/ mice upon evaluating path length (genotype x time:
F4,172 ¼ 2.94, P ¼ 0.02; time: F4,172 ¼ 4.15, P ¼ 0.003; Fig. 4A) and time
in periphery (genotype x time: F4,172 ¼ 3.25, P ¼ 0.01; time: F4,172 ¼ 6.94;
Fig. 4B). These effects were most pronounced on the sixth day of training
and were not caused by motor impairment as no difference in velocity
was observed (t48 ¼ 0.21, P ¼ 0.83, data not shown). Cognitive flexi-
bility, as measured during reversal learning, was similar for A20þ/ and
WT littermates (Fig. 4C and D). Despite A20þ/ mice showing a signifi-
cant preference for the target quadrant during the probe trial of reversal
learning (Fig. 4E), only WT animals showed a significant preference for
the location of the reversal platform in comparison to its previous7
location during acquisition (Fig. 4F). This was measured by comparing
the total distance towards the location of both platforms. It indicates that
the memory formation regarding the new location of the platform was
not as robust in A20þ/ mice in comparison to the controls. Taken
together, A20þ/ mice show learning deficits during the second phase of
acquisition and a subtle memory impairment during reversal learning.
In summary, an acute endotoxin challenge in A20 heterozygous ani-
mals leads to the development of behavioral symptoms are observed up
to 30 days after the injection. These phenotypes were predominantly
present in female A20þ/ mice and can be further characterized as
hypoactivity, anxiety-related behavior, cognitive impairment and deficits
in sensorimotor gating. It can be concluded that the presence of an
environmental stimulus is a crucial component in disease pathogenesis
and triggers more behavioral symptoms in a female-specific manner.
3.3. Sex-specific and context-dependent neuroinflammatory profile in
A20þ/ and WT mice
To investigate whether neuroinflammatory mechanisms underly the
observed behavioral phenotypes in A20þ/ mice, a gene expression
analysis was conducted using qRT-PCR. Since A20 is a crucial regulator
of the NF-κB pathway, the expression of several NF-κB target genes and
markers related to neuroinflammation were evaluated in hippocampal
and cortical brain tissue. The NF-κB target genes can be subdivided into
three groups encompassing (1) cytokines and chemokines, (2) regulators
of apoptosis and (3) regulators of the NF-κB pathway. The fourth group of
markers consists of genes that were previously found to be associated
with NPSLE in mice namely TWEAK (TNF related weak inducer of
apoptosis) and Lcn2 (Lipocalin 2) (Mike et al., 2019; Stock et al., 2013).
Furthermore, this group also contains markers including the
anti-inflammatory Tgfb, glial associated markers Iba1 (ionized calcium
Fig. 4. Learning and memory impair-
ment detected in A20þ/ mice after
acute LPS challenge.
(A) During the second phase of acquisi-
tion learning, A20þ/ mice had a longer
path length in comparison to WT litter-
mates. This was most pronounced on day
6; (B) A20þ/ mice spent more time in
the periphery, that was most pronounced
on the day 1 and 6; (C) A20þ/ and WT
littermates showed a similar perfor-
mance during reversal learning as evi-
denced by the similar pathlength; and
(D) time spent in the periphery; (E) Both
genotypes had a preference for the target
quadrant over the other quadrants dur-
ing the probe trial of reversal learning
(T: Target, O: Opposite, A1: Adjacent;
A2: Adjacent 2 quadrants); (F) For the
reversal probe trial, the total distance
towards the location of the platform
during acquisition and reversal learning
revealed that only WT mice show a sig-
nificant preference for the new location
of the platform; (Acq: Acquisition, Rev:
Reversal). Data are represented as
meanSEMs and statistical differences
were determined using repeated-
measures two-way ANOVA using Dun-
nett’s multiple comparisons test for post
hoc analysis (A-E) and two-way ANOVA
using Sidak’s multiple comparisons test
for post hoc analysis (F); (*P < 0.05, **P
< 0.01, ***P < 0.001, ****P < 0.0001).
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as Nox2, a marker for oxidative stress.
Under baseline conditions at the age of 3 months, a subtle neuro-
inflammatory phenotype is observed in the hippocampus of A20þ/ male
mice (Fig. 5A). In comparison to WT littermates, NF-κB activity is
induced as observed by the significant upregulation of Ikb (inhibitor of NF-
κB), (t10 ¼ 3.46, p ¼ 0.006). The pro-inflammatory cytokine Tnf (t10 ¼
2.26, p ¼ 0.04) and the anti-apoptotic protein Bcl-2-related protein A1
(Bfl1) (t10 ¼ 2.29, p ¼ 0.04) are the only NF-κB target genes that show a
significant upregulation. Looking at neuroinflammation in general,
increased expression of the anti-inflammatory cytokine Tgfb (Mann-
Whitney U ¼ 1, p ¼ 0.004), and the marker for oxidative stress (Nox2: t9
¼ 3.17, p ¼ 0.01) were observed. Heterozygosity was confirmed by the
50% reduction in A20 expression in heterozygous animals (male A20: t10
¼ 3.34, p ¼ 0.0075; female A20: t9 ¼ 4.16, p ¼ 0.002).
In female A20þ/ mice, the only NF-κB target gene that shows a
significant upregulation is C-X-C motif chemokine 10 (Cxcl10, t9 ¼ 6.44, p
¼ 0.0001; Fig. 5A). Evaluating general markers for neuroinflammation
indicates a significant upregulation of the astrocyte marker Gfap (t9 ¼
2.57, p ¼ 0.03) and borderline significance for oxidative stress (Nox2: t7
¼ 2.11, p ¼ 0.07) and microglial activity (Iba1: t9 ¼ 1.94, p ¼ 0.08).
Overall, it can be concluded that female A20þ/ mice show little acti-
vation of the NF-κB pathway and subtle increase in markers related to
neuroinflammation.
At the age of 6 months, a different neuroinflammatory phenotype is
observed in females with increased expression of several NF-κB regulated8
cytokines, chemokines and regulators of apoptosis (Fig. 5C). An
increased expression of the pro-inflammatory cytokines Il1b (t10 ¼ 3.92,
p ¼ 0.002) and Tnf was observed (t10 ¼ 3.29, p ¼ 0.008), as well as a
significant downregulation of the anti-inflammatory cytokine Interleukin
10 (Il10: t7¼ 3.30; p¼ 0.01). C–C-Motif Chemokine ligand 2 (Ccl2) showed
a significant upregulation (t9 ¼ 4.51, p ¼ 0.001), whereas a significant
downregulation was found for Interleukin 8 (Il8MannWhitney U¼ 0, p¼
0.01). Both are important pro-inflammatory chemokines in which Ccl2
attracts monocytes, T-lymphocytes and natural killer cells, whereas Il8 is
mainly a chemotactic for neutrophils. Several regulators of apoptosis
were also significantly upregulated including Bfl1 (t10 ¼ 4.39, p¼ 0.001)
and Baculoviral IAP repeat-containing protein 2, Birc2 (Mann Whitney U ¼
1, p ¼ 0.004). Borderline significance was observed for the X-linked in-
hibitor of apoptosis protein, Xiap (t10 ¼ 2.17, p ¼ 0.055). All three genes
encode for anti-apoptotic proteins of which Birc2 and Xiap belong to the
inhibitor of apoptosis (IAP) family that exert their function by interacting
with caspases (Yi Li and Ming Li, 2000). Bfl1, on the other hand, belongs
to the Bcl2 family that controls cell death by regulating mitochondrial
outer membrane permeabilization (Kale et al., 2018). Furthermore, a
significantly upregulated expression was observed for Nox2 (t10 ¼ 4.08,
p ¼ 0.002) and Lcn2 (Mann Whitney U ¼ 0, p ¼ 0.004). Lcn2 protein has
pleiotropic functions that involve regulation of innate immunity, cellular
differentiation and survival (Mike et al., 2019). This protein is also found
to be upregulated in SLE and a knockout of this gene in a lupus mouse
model improved depression-like behavior and cognitive defects (Mike
et al., 2019).
Fig. 5. Sex-specific and context-dependent neuroinflammatory profile observed in A20þ/ and WT littermates.
The neuroinflammatory profile in the hippocampus of female and male A20þ/ and WT mice was determined using NF-κB target genes (group 1–3) as markers as well
as markers for general neuroinflammation (group 4). The NF-κB target genes can be subdivided into cytokines and chemokines (group 1), anti-apoptotic mediators
(group 2) and regulators of NF-κB activity (group 3); (A) Subtle neuroinflammation was observed in female and male A20þ/ mice. For every sample n ¼ 5; (B). A
female predominant neuroinflammatory phenotype was observed in A20þ/ and WT mice 30 days after LPS challenge. For every sample n ¼ 6; (C) At the age of 6
months neuroinflammation was predominantly observed in A20þ/ female mice. For every sample, n ¼ 6. Statistical differences were determined using the unpaired t-
test or Mann Whitney test (A-C) (*P < 0.05, **P < 0.01, ****P < 0.0001, # borderline significance 0.05 < P < 0.08).
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cognitive phenotyping, hippocampal samples were isolated to evaluate
their neuroinflammatory profile at the age of 6 months. Surprisingly, we
did not observe the same pro-inflammatory response as seen in females.
Borderline significance was found for Ikb (t10 ¼ 1.98, p ¼ 0.07). Besides
an upregulation for Lcn2 (t10 ¼ 3.44, p ¼ 0.006) and C–C motif chemokine
ligand 5 (Ccl5) (t10 ¼ 2.98, p ¼ 0.01), significant downregulation was
observed for Xiap (t10 ¼ 2.60, p ¼ 0.02) and Iba1 and Gfap, markers for
microglial and astrocytes, respectively (Iba1: Mann Whitney test: U ¼ 3,
p ¼ 0.03; Gfap: Mann Whitney test: U ¼ 3, p ¼ 0.01).
In summary, aging has sex-specific effects on the neuroinflammatory
phenotype in A20þ/ mice. In male A20þ/ mice, a subtle increase in NF-
κB pathway activity and general inflammation was seen at the age of 3
and 6 months. For females, low-grade neuroinflammation was observed
at the age of 3 months that became more pronounced with age.
Besides the effect of A20 heterozygosity on neuroinflammation, we
also evaluated the influence of an environmental challenge (Fig. 5B). In
female A20þ/ mice, the prominent neuroinflammatory phenotype
included the upregulation of multiple NF-κB target genes. Increased
expression of pro-inflammatory cytokines Il1b (t10¼ 3.68, p¼ 0.004) and
Tnf (t10¼ 2.49, p¼ 0.03) as well as the upregulation of pro-inflammatory
chemokines Il8, Ccl2 and Cxcl10 (Il8: t7¼ 2.27, p¼ 0.057; Ccl2: t9¼ 2.11,
p ¼ 0.06; Cxcl10: t10 ¼ 2.75, p ¼ 0.02). Several genes encoding anti-
apoptotic proteins also showed an increased expression, including Bfl1,
Xiap and Birc3 (Baculoviral IAP Repeat Containing 3) (Bfl1: t8 ¼ 2.93, p ¼
0.01; Xiap: t10¼ 1.96, p¼ 0.07; Birc3: t10¼ 2.25, p¼ 0.04). Furthermore,
increased expression of oxidative stress marker Nox2 (t9 ¼ 3.65, p ¼
0.005), Lcn2 (t7 ¼ 4.94, p ¼ 0.001) and a significant downregulation of
astrocyte marker Gfap (t10 ¼ 4.31, p ¼ 0.015) were observed. In male
A20þ/ mice, the LPS challenge only resulted in an upregulation of the
pro-inflammatory cytokine Il1b (t10 ¼ 2.76, p ¼ 0.02) and a borderline
significance for Cxcl10 (t9 ¼ 2.06, p ¼ 0.06). For both A20þ/ females as
well as A20þ/ males, heterozygosity was confirmed (female A20: t10 ¼9
6.54, p < 0.0001; male A20: Mann Whitney U ¼ 0, p ¼ 0.002).
To estimate the extent of the inflammatory response, the expression
levels of a limited set of genes was evaluated in the cortex (Fig. 6). At the
age of 3 months, only females showed a significant upregulation of the
inflammatory cytokine Il1b (t6 ¼ 4.04, p ¼ 0.006; Fig. 6A). Even though
A20þ/ male mice developed spontaneous neuroinflammation in the
hippocampus, no increased expression of inflammatory cytokines was
observed in the cortex. At the age of 6 months, an increased expression of
Il1b (t10 ¼ 4.91; p ¼ 0.0006) and Lcn2 (Mann Whitney U ¼ 0, p ¼ 0.004)
was observed specifically in females (Fig. 6C). A20þ/ male mice also
showed a significant upregulation of Il1b (t9 ¼ 2.56, p ¼ 0.03) and
borderline significance for Lcn2 (t10 ¼ 2.08; p ¼ 0.06). Furthermore, a
significant downregulation of Tgfb was observed (t10 ¼ 3.74, p ¼ 0.003).
This indicates that in females at the age of 6 months the observed neu-
roinflammation is not restricted to the hippocampus, while also in male
A20þ/ mice, a subtle increase in neuroinflammation is observed in
cortical samples.
Analysis of cortical inflammation of LPS-injected mice showed a
strong neuroinflammatory response in female A20þ/ mice, whereas
almost no sign of inflammation was detected in male A20þ/ mice.
Significant increases in Nox2 (t10 ¼ 5.84, p ¼ 0.0002) and Lcn2 (t10 ¼
4.68, p¼ 0.009; Fig. 6B) were observed as well as borderline significance
for the pro-inflammatory cytokines Il1b (t9 ¼ 2.06, p ¼ 0.06) and Tnf (t10
¼ 2.01, p ¼ 0.07) (Fig. 6B). Together, these results indicate that one
single immune challenge results in widespread, chronic neuro-
inflammation in A20þ/ female mice, but not in A20þ/ male mice.
3.4. Normal white blood cell count and an intact blood-brain barrier were
observed in A20 heterozygous mice
White blood cell related markers were evaluated to determine the
presence of peripheral inflammation. Under baseline conditions, no in-
crease was observed in the total white blood cell count for females (t5 ¼
Fig. 6. Cortical inflammatory profile of A20þ/ and WT littermates.
A limited set of neuroinflammatory markers was evaluated on cortical samples. (A) At the age of 3 months, only a significant upregulation was observed for the pro-
inflammatory cytokine interleukin 1b (Il1b) in female A20þ/ mice; (B) 30 days after injection of LPS, inflammation was only observed in female A20þ/ mice in
comparison to WT littermates. The inflammatory response was characterized by a significant increase in Nox2 (oxidative stress) and lipocalin 2 (Lcn2) as well as
borderline significance for pro-inflammatory cytokines Il1b and Tnf; (C) At the age of 6 months, females showed a significant increase in the pro-inflammatory
cytokine Il1b and Lcn2. In male A20þ/ mice, upregulation for Il1b and downregulation of Tgfb were observed. Statistical differences were determined using un-
paired t-test or Mann Whitney U test (A-C) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, # borderline significance 0.05 < P < 0.08).
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of 3 months. Similar results were observed upon analyzing samples ob-
tained from 6 months old female mice (Mann Whitney U ¼ 65.50, p ¼
0.80; Fig. 7C) and males (t19 ¼ 0.35, p ¼ 0.72; Fig. 7D). The same ana-
lyses were performed to exclude peripheral inflammation after LPS im-
mune challenge (Fig. 7E and F). This analysis was performed 30 days
post-LPS injection after completion of the behavioral protocol. No dif-
ference was observed in absolute leukocyte count for A20þ/ female and
male mice in comparison toWT littermates (females: t14¼ 1.46, p¼ 0.17;
males: t18 ¼ 0.64, p ¼ 0.53). Together, these results show that the
behavioral and inflammatory phenotypes at baseline conditions and after
an immune challenge occur in the absence of peripheral inflammation.
The blood-brain barrier (BBB) is a tightly regulated neurovascular
unit that controls access of molecules and cells between plasma and brain
(Sweeney et al., 2019). For long, the disruption of the BBB was consid-
ered a central event in the pathogenesis of neuropsychiatric lupus.
However, the question remains whether an increased BBB permeability
contributes to the development of diffuse symptoms or whether it occurs
in later stages of the disease. We found no difference in BBB permeability
in 6 months old and LPS injected A20þ/ and WT mice (Fig. 7G–J). This
observation is consistent with the previously observed absence of BBB
disruption in 4–5 weeks old A20 heterozygous and knockout mice
(Guedes et al., 2014). These findings further support the ‘CNS primary
hypothesis’ and indicate that BBB disruption is probably not important in
the early stages of disease development.
4. Discussion
4.1. Behavioral phenotypes in young A20 heterozygous mice show no sex
bias, originate in the CNS and have distinct inflammatory profiles
The pathogenesis of neuropsychiatric symptoms is incompletely un-
derstood and controversy consists regarding their etiology. In this paper,
we have evaluated the contribution of CNS-intrinsic mechanisms to the
development of neuropsychiatric symptoms using the A20 heterozygous
mouse model.10First, we observed subtle cognitive deficits in A20 heterozygous mice
3 months of age. This was accompanied by a subtle neuroinflammatory
phenotype in hippocampus and cortex. Neuroinflammation was observed
in females and males alike but was characterized by the upregulation of
different markers. A20þ/ female mice mainly showed upregulation of
the chemokine Cxcl10 in hippocampus and pro-inflammatory cytokine
Il1b in cortex. A20þ/ male mice, on the other hand, showed increased
activation of the NF-κB pathway in the hippocampus accompanied by
increased expression of pro- and anti-inflammatory as well as anti-
apoptotic genes. Previously, the neuroinflammatory profile of A20 het-
erozygous mice was evaluated at the age of 4–5 weeks, and revealed a
trend towards increased basal inflammation in comparison to WT con-
trols, albeit not statistically significant (Guedes et al., 2014). Here, the
use of a more extensive set of markers revealed subtle neuroinflammation
in male and female mice at the age of 19 weeks.
Neuropsychiatric symptoms can develop before the onset of SLE or
very early after the diagnosis and they are not associated with markers of
peripheral disease activity (Hanly et al., 2007; Magro-Checa et al., 2019;
Petri et al., 2010; Shimojima et al., 2005; van Dam et al., 1994). There-
fore, we investigated whether peripheral inflammation may have
contributed to the development of spontaneous neuroinflammation and
behavioral phenotypes. White blood cells comprise granulocytes, lym-
phocytes and monocytes that exert important roles in the defense against
infection (Blumenreich, 1990). An increase in total white blood cell
count is an indication for an increased inflammatory response. In SLE, a
decrease in total white blood cell count is commonly observed (Fayyaz
et al., 2015). Similar to neuropsychiatric symptoms, it is important to
make a distinction between leukopenia caused by SLE itself or as a sec-
ondary consequence by immunosuppressive treatment (Fayyaz et al.,
2015). In A20 heterozygous mice, we did not observe a difference in total
white blood cell count, indicating there is no peripheral inflammation.
This is supported by findings from Studer et al. in which it was seen that
A20 heterozygosity did not result in hyperactivation of the innate and
adaptive immune system (Studer et al., 2015). Furthermore, no increased
BBB permeability was observed in A20 heterozygous mice (Guedes et al.,
2014).
Fig. 7. Evaluation of white blood cell count and blood-brain barrier permeability.
The presence of peripheral inflammation was measured by the total white blood cell count (WBC). For all conditions (baseline 3m
(A-B), baseline 6m (C-D) and LPS injection (E-F) no differences between A20þ/ mice and wildtype littermates was observed. No differences were found in BBB
permeability when evaluating 6 months old (G-H) and LPS injected mice (I-J). Statistical differences were determined using unpaired t-test or Mann Whitney test
(A-J).
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the different composition, tend towards a moderate proinflammatory
state that correlates with the subtle cognitive phenotype.4.2. Female-biased behavioral phenotypes in A20 heterozygotes arise with
age
Systemic lupus erythematosus occurs predominantly in females with
a peak incidence at the age of 30–70 years old (Rees et al., 2017).
Therefore, we evaluated the behavior of A20þ/ female mice at the age of
6 months, equivalent to 30 years of age in humans and observed a subtle
impairment in cognitive flexibility. The neuroinflammatory profile of
female A20þ/ mice showed a significant upregulation of several NF-κB
target genes including pro-inflammatory cytokines, chemokines and
anti-apoptotic mediators. In contrast, only a subtle neuroinflammatory
profile was observed in male A20þ/ mice. Since no significant differ-
ences were observed in the total white blood cell count and BBB
permeability, we conclude that the neuroinflammation was initiated by
CNS intrinsic mechanisms.
Aging is accompanied by a decrease in cognitive abilities (Barrientos
et al., 2015; Di Benedetto et al., 2017). The underlying mechanisms are
not fully understood, but neuroinflammation plays an important role
(Berchtold et al., 2008; Niraula et al., 2017). An upregulation of in-
flammatory mediators was observed when comparing human brain
samples from young (20–59 years) and old (60–99 years) females and
males, but it was proportionally greater in females (Berchtold et al.,112008). This indicates that the magnitude of neuroinflammation with
aging is sex-specific. Age-associated neuroinflammation can largely be
attributed to changes in microglia, resident immune cells of the CNS with
important functions in maintaining CNS homeostasis (Li and Barres,
2017; Mangold et al., 2017; Niraula et al., 2017). With age, microglia
acquire a ‘primed’ phenotype, which is characterized by a slower initi-
ation, but more sustained and uncontrolled inflammatory response
(Damani et al., 2011; Perry and Holmes, 2014; Streit et al., 2004). A20 is
mainly expressed in microglia and deletion of A20 in microglia results in
microglial activation and synaptic dysfunction and cognitive defects
(Zhang et al., 2014; Voet et al., 2018), while targeted knockout of A20 in
neurons, astrocytes and oligodendrocytes did not lead to spontaneous
CNS inflammation (Guedes et al., 2014; X. Wang et al., 2013). Therefore,
it is likely that microglia have an important contribution to the
sex-specific neuroinflammatory phenotype observed in A20 heterozy-
gous mice at the age of 6 months.
Taken together, we propose that CNS-intrinsic mechanisms underly
the behavioral phenotype observed in A20þ/ female mice at the age of 6
months. Furthermore, the sex-specific neuroinflammatory profile can
probably be explained by an increased activation of microglial cells that
occurs with age.4.3. Immune challenge triggers neurobehavioral phenotypes in A20
heterozygous females
NPSLE is characterized by a complex interplay between genetic,
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ronmental stimuli that can trigger or worsen SLE (Ribeiro and Signorelli,
2017). To mimic the disease pathology more closely, an acute immune
challenge using a single dose of LPS, resembling an infection, was
delivered in the intraventricular system of A20þ/ and wildtype mice.
Behavioral outcomes were followed up until one month after LPS
administration. This resulted in several behavioral impairments and
chronic inflammation that were predominantly observed in female
A20þ/ mice. The observed behavioral phenotypes included hypo-
activity, anxiety-like behavior, cognitive impairment and prepulse inhi-
bition and were found in the absence of peripheral inflammation. Except
for hypoactivity, which reflects a decrease in general well-being in the
first days after the injection, all other behavioral impairments can be
translated to NPSLE patients. According to a recently performed
meta-analysis, anxiety disorders are found in up to 40% of SLE patients
and similar percentages have been reported for NPSLE (Jeltsch-David
and Muller, 2014; Rees et al., 2017). Mild-to-moderate cognitive im-
pairments are found in up to 80% of patients and have been shown to be
unrelated to systemic disease activity and duration (Hanly and Harrison,
2005; Mak et al., 2009). In contrast, it was shown that cognitive
impairment is more related to the presence of depression, anxiety and
stress (Monastero et al., 2001; Montero-Lopez et al., 2016). Prepulse
inhibition is a very sensitive and robust measure for sensorimotor gating,
a mechanism that filters irrelevant sensory stimuli in order to avoid an
overload of sensory information (Swerdlow et al., 2008). PPI impair-
ments are found in several neuropsychiatric disorders and are related to
both cognitive and functional deficits, like psychosis (Kohl et al., 2013;
Mena et al., 2016; Swerdlow et al., 2008). Despite the fact that cognitive
deficits as well as primary acute psychosis have been reported in NPSLE
patients and that the presence of psychosis is regarded as one of the
classification criteria for systemic lupus erythematosus, no studies
investigating prepulse inhibition in patients have been reported up until
now (Appenzeller et al., 2008; ACR, 1999).
Thirty days after LPS challenge, a strong and widespread neuro-
inflammatory response was observed predominantly in 3-month old
A20þ/ female mice. This profile is comparable to what is seen in 6-
month old mice without immune challenge. The response was also
characterized by a strong upregulation of NF-κB target genes encoding
pro-inflammatory cytokines, chemokines and anti-apoptotic proteins as
well as general markers of neuroinflammation. In contrast, A20þ/ male
mice displayed a low-grade spontaneous neuroinflammatory phenotype.
Again, no differences in total white blood cell count and BBB perme-
ability were observed between A20 heterozygous mice and WT litter-
mates indicating that peripheral inflammation was not an important
factor in the inflammatory phenotypes.
Sex-related differences in immune and autoimmune responses are
well described and conserved in different species (Klein and Flanagan,
2016). However, this strong immune activity is a double-edged sword as
it also makes females more prone to the development of inflammatory
and autoimmune disorders (Rubtsova et al., 2015). For systemic lupus
erythematosus, a bias towards females with a 9:1 or even 15:1 fema-
le/male ratio has been observed (Petri, 2002; Rubtsov et al., 2010;
Zandman-Goddard et al., 2012). The A20 heterozygous mouse model
recapitulates a similar bias since behavioral impairments and neuro-
inflammation were mostly found in female mice at the age of 6 months
and after LPS injection. Various factors have been proposed to explain
this sex-specific bias, including sex hormones, X chromosome-linked ef-
fects and environmental factors such as diet (Rubtsova et al., 2015). Since
A20 is not X chromosome-linked (chromosomes 10A3 in mice, 6q23.3 in
humans) and the diet of A20 heterozygous male and female mice was the
same, the most likely explanation for the differences are sex hormones. It
has been described that 17-β-estradiol (E2) is an inhibitor of TNFAIP3
expression in breast carcinoma cells from postmenopausal women as
seen in a significant downregulation of A20 expression (Vendrell et al.,
2007). Furthermore, estrogen was found to increase the susceptibility for
SLE and had an effect on the development of SLE flares (Bernier et al.,122009; Buyon et al., 2005; Costenbader et al., 2007; Hughes and Choubey,
2014).
Several cytokines and chemokines, that were upregulated in A20þ/
female mice after LPS injection and at the age of 6 months, are also
proposed as potential biomarkers for NPSLE (Jeltsch-David and Muller,
2014). This was based on the presence of cytokines (Il1, IL10, Tnf) and
chemokines (Il8, Ccl2, Cxcl10) in cerebrospinal fluid of patients
(Jeltsch-David and Muller, 2014). Furthermore, we also observed upre-
gulation of Lcn2. This lipophilic protein was originally shown to play an
important role in preventing bacterial outgrowth by sequestration of
iron-loaded siderophores (Flo et al., 2004). It is a marker for neuro-
inflammation with a strong and rapid induction by activated microglia
and astrocytes after LPS challenge (Bennett et al., 2016; Zamanian et al.,
2012). Recently, Lcn2 was discovered to be a key mediator in the path-
ogenesis of neuropsychiatric lupus using a Sle1,3 mouse model (Mike
et al., 2019). Lcn2 deficiency improved behavioral readouts related to
depression, motor coordination and spatial memory as well as neuro-
inflammation (Mike et al., 2019). Importantly, Lcn2 deficiency had no
influence on peripheral inflammation, indicating that the effect was
primarily achieved via brain-intrinsic pathways. Lcn2 is a known target
gene of the Il17 signaling pathway (Shen et al., 2006). Il17 is an
important key player in autoimmune inflammation and increased serum
levels are also found in NPSLE (Vincent et al., 2013). Il17 can induce
activation of the NF-κB pathway (Shen et al., 2006). Previously, it was
shown that A20 is a negative regulator of the Il17 mediated signaling
pathway and that A20 deficiency in vitro is associated with a strong
upregulation of Lcn2 (Grag et al., 2013). These results connect A20
heterozygosity with neuropsychiatric lupus at the molecular level.
4.4. A mouse model for neuropsychiatric lupus
For several reasons, the A20 heterozygous mouse model can
contribute to future research investigating the pathophysiology of
NPSLE. First of all, this model identifies a genetically predisposing factor
that can lead to the development of neuropsychiatric symptoms via
brain-intrinsic mechanisms. Furthermore, in the pathogenesis of NPSLE
the contribution of environmental stimuli are considered to be important
triggers in genetically predisposed persons. This was confirmed by the
observations that behavioral phenotypes were exacerbated in the A20
heterozygous mouse model after exposing them to an immune challenge.
Moreover, these phenotypes were predominantly found in females, a
third important feature observed in NPSLE. Another advantage of this
mouse model, is that the influence of A20 heterozygosity was evaluated
in C57BL/6, a genetic background known to be permissive for lupus
development but not spontaneously inducing it (Crampton et al., 2014).
This is in sharp contrast with the spontaneous mouse models that are
currently used for NPSLE research (Pikman et al., 2017; Schwartz et al.,
2019). Even though these spontaneous models of SLE are invaluable,
their main drawback is that none of them have mutations in genes that
are associated with SLE (Schwartz et al., 2019). For example, the
MRL/Lpr model, which is most extensively investigated in NPSLE-related
research, is characterized by abnormal expression of the Fas gene (Wat-
son et al., 1992). Fas-deficiency in humans is associated with lymph-
adenopathies, but they do not develop a lupus-like phenotype
(Rensing-ehl et al., 2014). By contrast, A20 haploinsufficiency in humans
was associated with the development of an early-onset autoimmune
disorder, of which at least one patient was diagnosed with a condition
resembling SLE (Zhou et al., 2015). The recent identification of a
frameshift mutation in TNFAIP3 in a patient with NPSLE (Duan et al.,
2019) provides further support for the validity of our model.
5. Conclusion
We have shown that heterozygosity for A20 defines a genetic mouse
model that recapitulates numerous hallmark features of neuropsychiatric
lupus including high prevalence in females, worsening of phenotypes
C. Daems et al. Brain, Behavior, & Immunity - Health 2 (2020) 100018with age and upon exposure to an environmental stimulus that mimics
infection. Our results are consistent with the CNS primary hypothesis that
posits that initial neuroinflammatory changes in the CNS are responsible
for behavioral phenotypes observed in patients with neuropsychiatric
lupus. We propose that this mouse model provides novel opportunities to
gain mechanistic insight in pathological mechanisms of neuropsychiatric
lupus, in disease progression, and conceivably into therapeutic targets.
Ethics approval




Availability of data and material
All data generated and analyzed in the course of this study are
included in the main manuscript and in the supplementary information
files.
Funding
Carmen Daems was supported by a fellowship of the Flemish
Research Foundation.
Authors’ contributions
CD, ZCV and PC designed the study. CD performed the majority of
experiments with the help of MS for behavioral testing and of VV for gene
expression analysis. RD provided the behavioral setups for performing all
analyses and the stereotactic frame for ICV injections. GvL generated the
A20FL mice used for breeding. CD and ZCV performed statistical analyses
and CD, ZCV and PC analyzed and interpreted results. CD, RD, GvL, ZCV
and PC wrote the manuscript.Declaration of competing interest
None.
Acknowledgements
This study was supported by a fellowship from FWO to CD. Research
in the GvL lab is supported by research grants from the FWO, the
“Geneeskundige Stichting Koningin Elisabeth” (GSKE), the CBC Banque
Prize, the Charcot Foundation, the “Belgian Foundation against Cancer”,
“Kom op tegen Kanker”, and the GOA of the Ghent University.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://do
i.org/10.1016/j.bbih.2019.100018.
References
ACR, 1999. The American College of Rheumatology nomenclature and case definitions
for neuropsychiatric lupus syndromes. Arthritis Rheum. 42, 599–608.
Adrianto, I., Wen, F., Templeton, A., Wiley, G., King, J.B., Lessard, C.J., Bates, J.S., Hu, Y.,
Kelly, J.A., Kaufman, K.M., Guthridge, J.M., Alarcon-Riquelme, M.E., Anaya, J.M.,
Bae, S.-C., Bang, S.-Y., Boackle, S.A., Brown, E.E., Petri, M.A., Gallant, C., Ramsey-
Goldman, R., Reveille, J.D., Vila, L.M., Criswell, L.A., Edberg, J.C., Freedman, B.I.,
Gregersen, P.K., Gilkeson, G.S., Jacob, C.O., James, J.A., Kamen, D.L., Kimberly, R.P.,
Martin, J., Merrill, J.T., Niewold, T.B., Park, S.-Y., Pons-Estel, B.A., Scofield, R.H.,
Stevens, A.M., Tsao, B.P., Vyse, T.J., Langefeld, C.D., Harley, J.B., Moser, K.L.,
Webb, C.F., Humphrey, M.B., Montgomery, C.G., Gaffney, P.M., 2011. Association of13a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat.
Genet. 43, 253–258.
Appenzeller, S., Cendes, F., Costallat, L.T.L., 2008. Acute psychosis in systemic lupus
erythematosus. Rheumatol. Int. 28, 237–243.
Barrientos, R., Kitt, M., Watkins, L., Maier, S., 2015. Neuroinflammation in the normal
aging hippocampus. Neuroscience 309, 84–99.
Bendorius, M., Po, C., Muller, S., Jeltsch-David, H., 2018. From systemic inflammation to
neuroinflammation: the case of neurolupus. Int. J. Mol. Sci. 19, 3588.
Bennett, M.L., Bennett, F.C., Liddelow, S.A., Ajami, B., Zamanian, J.L., Fernhoff, N.B.,
Mulinyawe, S.B., Bohlen, C.J., Adil, A., Tucker, A., Weissman, I.L., Chang, E.F., Li, G.,
Grant, G.A., Gephart, M.G.H., Barres, B.A., 2016. New tools for studying microglia in
the mouse and human CNS. Proc. Natl. Acad. Sci. 113, E1738–E1746.
Berchtold, N.C., Cribbs, D.H., Coleman, P.D., Rogers, J., Head, E., Kim, R., Beach, T.,
Miller, C., Troncoso, J., Trojanowski, J.Q., Zielke, H.R., Cotman, C.W., 2008. Gene
expression changes in the course of normal brain aging are sexually dimorphic. Proc.
Natl. Acad. Sci. 105, 15605–15610.
Bernier, M., Mikaeloff, Y., Hudson, M., Suissa, S., 2009. Combined oral contraceptive use
and the risk of systemic lupus erythematosus. Arthritis Rheum. 61, 476–481.
Blumenreich, M.S., 1990. The white blood cell and differential count. In: Clinical
Methods: the History, Physical, and Laboratory Examinations, third ed., pp. 724–727.
Bortoluzzi, A., Scire, C.A., Govoni, M., 2018. Attribution of neuropsychiatric
manifestations to systemic lupus erythematosus. Front. Med. 5, 1–5.
Bosanac, I., Wertz, I.E., Pan, B., Yu, C., Kusam, S., Lam, C., Phu, L., Phung, Q., Maurer, B.,
Arnott, D., Kirkpatrick, D.S., Dixit, V.M., Hymowitz, S.G., 2010. Ubiquitin binding to
A20 ZnF4 is required for modulation of NF-kB signaling. Mol. Cell 40, 548–557.
Brody, D.L., Holtzman, D.M., 2006. Morris water maze search strategy analysis in PDAPP
mice before and after experimental traumatic brain injury. Exp. Neurol. 197,
330–340.
Bryant, C.E., Spring, D.R., Gangloff, M., Gay, N.J., 2010. The molecular basis of the host
response to lipopolysaccharide. Nat. Rev. Microbiol. 8, 8–14.
Buyon, J.P., Petri, M.A., Kim, M.Y., Kalunian, K.C., Grossman, J., Hahn, B.H., 2005. The
effect of combined estrogen and progesterone hormone replacement therapy on
disease activity in. Systemic Lupus. Ann. Intern. Med. 142, 953–962.
Callaerts-Vegh, Z., Beckers, T., Ball, S.M., Baeyens, F., Callaerts, P.F., Cryan, J.F.,
Molnar, E., D’Hooge, R., Hooge, R.D., D’Hooge, R., 2006. Concomitant deficits in
working memory and fear extinction are functionally dissociated from reduced
anxiety in metabotropic glutamate receptor 7-deficient mice. J. Neurosci. 26,
6573–6582.
Callaerts-Vegh, Z., Leo, S., Vermaercke, B., Meert, T., D’Hooge, R., 2012. LPA 5 receptor
plays a role in pain sensitivity , emotional. Genes Brain Behav. 11, 1009–1019.
Costenbader, K.H., Feskanich, D., Stampfer, M.J., Karlson, E.W., 2007. Reproductive and
menopausal factors and risk of systemic lupus erythematosus in women. Arthritis
Rheum. 56, 1251–1262.
Crampton, S.P., Morawski, P.A., Bolland, S., 2014. Linking susceptibility genes and
pathogenesis mechanisms using mouse models of systemic lupus erythematosus. Dis.
Model. Mech. 7, 1033–1046.
D’Hooge, R., De Deyn, P.P., Hooge, R.D., Deyn, P.P. De, 2001. Applications of the Morris
water maze in the study of learning and memory. Brain Res. Rev. 36, 60–90.
D’Hooge, R., Lüllmann-Rauch, R., Beckers, T., Balschun, D., Schwake, M., Reiss, K., von
Figura, K., Saftig, P., 2005. Neurocognitive and psychotiform behavioral alterations
and enhanced hippocampal long-term potentiation in transgenic mice displaying
neuropathological features of human alpha-mannosidosis. Neurobiol. Dis. 25,
6539–6549.
Damani, M.R., Zhao, L., Fontainhas, A.M., Amaral, J., Fariss, R.N., Wong, W.T., 2011.
Age-related alterations in the dynamic behavior of microglia. Aging Cell 10,
263–276.
De, A., Dainichi, T., Rathinam, C.V., Ghosh, S., 2014. The deubiquitinase activity of A20 is
dispensable for NF-kB signaling. EMBO Rep. 15, 775–783.
Devraj, K., Guerit, S., Macas, J., Reiss, Y., 2018. An in vivo blood-brain barrier
permeability assay in mice using fluorescently labeled tracers. J. Vis. Exp. 132
https://doi.org/10.3791/57038.
Di Benedetto, S., Müller, L., Wenger, E., Düzel, S., Pawelec, G., 2017. Contribution of
neuroinflammation and immunity to brain aging and the mitigating effects of
physical and cognitive interventions. Neurosci. Biobehav. Rev. 75, 114–128.
Duan, R., Liu, Q., Li, J., Bian, X., Yuan, Q., Li, Y., Long, F., Gao, S., 2019. A de novo
frameshift mutation in TNFAIP3 impairs A20 deubiquitination function to cause
neuropsychiatric systemic lupus erythematosus. J. Clin. Immunol. 39, 795–804.
Evans, P.C., Ovaa, H., Hamon, M., Kilshaw, P.J., Hamm, S., Bauer, S., Ploegh, H.L.,
Smith, T.S., 2004. Zinc-finger protein A20, a regulator of inflammation and cell
survival, has de-ubiquitinating activity. Biochem. J. 378, 727–734.
Fayyaz, A., Igoe, A., Kurien, B.T., Danda, D., James, J.A., Stafford, H.A., Scofield, R.H.,
2015. Haematological manifestations of lupus. Lupus Sci. Med. 2, e000078.
Flo, T.H., Smith, K.D., Sato, S., Rodriguez, D.J., Holmes, M.A., Strong, R.K., Akira, S.,
Aderem, A., 2004. Lipocalin 2 mediates an innate immune response to bacterial
infection by sequestrating iron. Nature 432, 917–921.
Flurkey, K., Currer, J., Harrison, D., 2007. The mouse in aging research. In: The Mouse in
Biomedical Research, pp. 637–672.
Gelb, S., Stock, A.D., Anzi, S., Putterman, C., Ben-zvi, A., 2018. Mechanisms of
neuropsychiatric lupus : the relative roles of the blood- cerebrospinal fl uid barrier
versus blood-brain barrier. J. Autoimmun. 91, 34–44.
Grag, A.V., Ahmed, M., Vallejo, A.N., Ma, A., Gaffen, S.L., 2013. The deubiquitinase A20
mediates feedback inhibition of interleukin-17 receptor signaling. Sci. Signal. 6, ra44.
Graham, R.R., Cotsapas, C., Davies, L., Hackett, R., Lessard, C.J., Leon, J.M., Burtt, N.P.,
Guiducci, C., Parkin, M., Gates, C., Plenge, R.M., Behrens, T.W., Wither, J.E.,
Rioux, J.D., Fortin, P.R., Cunninghame, D., Wong, A.K., Vyse, T.J., Daly, M.J.,
Altshuler, D., Moser, K.L., Gaffney, P.M., Graham, D.C., Wong, A.K., Vyse, T.J.,
C. Daems et al. Brain, Behavior, & Immunity - Health 2 (2020) 100018Daly, M.J., Altshuler, D., Moser, K.L., Gaffney, P.M., 2008. Genetic variants near
TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40,
1059–1061.
Guedes, R.P., Csizmadia, E., Moll, H.P., Ma, A., Ferran, C., da Silva, C.G., Gonçalves, C.,
2014. A20 deficiency causes spontaneous neuroinflammation in mice.
J. Neuroinflammation 11, 1–16.
Hanly, J.G., 2014. Diagnosis and management of neuropsychiatric SLE. Nat. Rev.
Rheumatol. 10, 338–347.
Hanly, J.G., Harrison, M.J., 2005. Management of neuropsychiatric lupus. Best Pract. Res.
Clin. Rheumatol. 19, 799–821.
Hanly, J.G., Urowitz, M.B., Bae, S.C., Gordon, C., Wallace, D.J., Isenberg, D., Alarco, G.S.,
Clarke, A., Bernatsky, S., Merrill, J.T., Petri, M., Dooley, M.A., Gladman, D.,
Fortin, P.R., Steinsson, K., Bruce, I., Manzi, S., Khamashta, M., Zoma, A., Aranow, C.,
Ginzler, E., Vollenhoven, R. Van, Font, J., 2007. Neuropsychiatric events at the time
of diagnosis of systemic lupus erythematosus an international inception cohort study.
Arthritis Rheum. 56, 265–273.
Hanly, J.G., Urowitz, M.B., Su, L., Bae, S.C., Gordon, C., Wallace, D.J., Clarke, A.,
Bernatsky, S., Isenberg, D., Rahman, A., Alarcon, G.S., Gladman, D.D., Fortin, P.R.,
Sanches-Guerrero, J., Romero-Diaz, J., Merrill, J.T., Ginzler, E., Bruce, I.N.,
Steinsson, K., Khamashta, M., Petri, M., Manzi, S., Dooley, M.A., Van Vollenhoven, R.,
Nived, O., Sturfelt, G., Aranow, C., Kalunian, K., Ramos-Casals, M., Zoma, A.,
Douglas, J., Thompson, K., Farewell, V., Vollenhoven, R. Van, Nived, O., Sturfelt, G.,
Aranow, C., Kalunian, K., Zoma, A., Douglas, J., Thompson, K., Farewell, V.,
International, L., 2010. Prospective analysis of neuropsychiatric events in an
international disease inception cohort of patients with systemic lupus erythematosus.
Ann. Rheum. Dis. 69, 529–535.
Hellemans, J., Mortier, G., De Paepe, A., Speleman, F., Vandesompele, J., 2007. qBase
relative quantification framework and software for management and automated
analysis of real-time quantitative PCR data. Genome Biol. 8, R19.
Hughes, G.C., Choubey, D., 2014. Modulation of autoimmune rheumatic diseases by
oestrogen and progesterone. Nat. Rev. Rheumatol. 10, 740–751.
Jeltsch-David, H., Muller, S., 2014. Neuropsychiatric systemic lupus erythematosus :
pathogenesis and biomarkers. Nat. Rev. Neurol. 10, 579–596.
Kale, J., Osterlund, E.J., Andrews, D.W., 2018. BCL-2 family proteins: changing partners
in the dance towards death. Cell Death Differ. 25, 65–80.
Kaul, A., Gordon, C., Crow, M.K., Touma, Z., Urowitz, M.B., Vollenhoven, R., Van, Ruiz-
irastorza, G., Hughes, G., van Vollenhoven, R., Ruiz-irastorza, G., Hughes, G., 2016.
Systemic lupus erythematosus. Nat. Rev. Dis. Primers 2, 16039.
Klein, S.L., Flanagan, K.L., 2016. Sex differences in immune responses. Nat. Rev.
Immunol. 16, 626–638.
Kohl, S., Heekeren, K., Klosterk€otter, J., Kuhn, J., 2013. Prepulse inhibition in psychiatric
disorders - apart from schizophrenia. J. Psychiatr. Res. 47, 445–452.
Lee, E., Boone, D., Chai, S., Libby, S., Chien, M., Lodolce, J., Ma, A., 2000. Failure to
regulate TNF-induced NF-kB and cell death responses in A20-deficient mice. Science
289, 2350–2354.
Li, Q., Barres, B.A., 2017. Microglia and macrophages in brain homeostasis and disease.
Nat. Rev. Immunol. 18, 225–242.
Lo, A.C., Callaerts-vegh, Z., Nunes, A.F., Rodrigues, C.M.P., Hooge, R.D., 2013.
Neurobiology of Disease Tauroursodeoxycholic acid ( TUDCA ) supplementation
prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol.
Dis. 50, 21–29.
Love, P.E., Santoro, S.A., 1990. Antiphospholipid antibodies: anticardiolipin and the
lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders:
prevalence and clinical significance. Ann. Intern. Med. 112, 682–698.
Lu, T.T., Onizawa, M., Hammer, G.E., Turer, E.E., Yin, Q., Damko, E., Agelidis, A.,
Shifrin, N., Advincula, R., Barrera, J., Malynn, B.A., Wu, H., Ma, A., 2013. Article
dimerization and ubiquitin mediated recruitment of A20 , a complex
deubiquitinating enzyme. Immunity 38, 896–905.
Ma, A., Malynn, B.A., 2012. A20: linking a complex regulator of ubiquitylation to
immunity and human disease. Nat. Rev. Genet. 12, 774–785. https://doi.org/
10.1038/nri3313.
Magro-Checa, C., Kumar, S., Ramiro, S., Voorde, L.J.B. De, Eikenboom, J., Ronen, I.,
Bresser, J. De, 2019. Are serum autoantibodies associated with brain changes in
systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort. Lupus 28,
94–103.
Mak, A., Chun Man Ho, R., Lau, C.S., 2009. Clinical implications of neuropsychiatric
systemic lupus erythematosus. Adv. Psychiatr. Treat. 15, 451–458.
Mangold, C.A., Wronowski, B., Du, M., Masser, D.R., Hadad, N., Bixler, G.V.,
Brucklacher, R.M., Ford, M.M., Sonntag, W.E., Freeman, W.M., 2017. Sexually
divergent induction of microglial- associated neuroinflammation with hippocampal
aging. J. Neuroinflammation 14, 1–19.
Mena, A., Ruiz-Salas, J.C., Puentes, A., Dorado, I., Ruiz-Veguilla, M., De la Casa, L.G.,
2016. Reduced prepulse inhibition as a biomarker of schizophrenia. Front. Behav.
Neurosci. 10, 202.
Mike, E.V., Makinde, H.M., Gulinello, M., Vanarsa, K., Herlitz, L., Gadhvi, G.,
Winter, D.R., Mohan, C., Hanly, J.G., Mok, C.C., Cuda, C.M., Putterman, C., 2019.
Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus.
J. Autoimmun. 96, 59–73.
Monastero, R., Bettini, P., Del Zotto, E., Cottini, E., Tincani, A., Balestrieri, G.,
Cattaneo, R., Camarda, R., Vignolo, L.A., Padovani, A., 2001. Prevalence and pattern
of cognitive impairment in systemic lupus erythematosus patients with and without
overt neuropsychiatric manifestations. J. Neurol. Sci. 184, 33–39.
Montero-Lopez, E., Santos-Ruiz, A., Navarrette-Navarette, N., Ortego-Centeno, N., Perez-
Garcia, M., Peralta-Ramirez, M., 2016. The effects of corticosteroids on cognitive
flexibility and decision-making in women with lupus. Lupus 25, 1470–1478.14Musone, S.L., Taylor, K.E., Lu, T.T., Nititham, J., Ferreira, R.C., Ortmann, W., Shifrin, N.,
Petri, M. a, Kamboh, M.I., Manzi, S., Seldin, M.F., Gregersen, P.K., Behrens, T.W.,
Ma, A., Kwok, P., Criswell, L. a, 2008. Multiple polymorphisms in the TNFAIP3 region
are independently associated with systemic lupus erythematosus. Nat. Genet. 40,
1062–1064.
Nadler, J., Moy, S., Dold, G., Trang, D., Simmons, N., Perez, A., Young, N., Barbaro, R.,
Piven, J., Magnuson, T., Crawley, J., 2004. Automated apparatus for quantitation of
social approach behaviors in mice. Genes Brain Behav. 3, 303–314.
Naert, A., Callaerts-Vegh, Z., D’Hooge, R., 2011a. Nocturnal hyperactivity , increased
social novelty preference and delayed extinction of fear responses in post-weaning
socially isolated mice. Brain Res. Bull. 85, 354–362.
Naert, A., Callaerts-Vegh, Z., Moechars, D., Meert, T., D’Hooge, R., 2011b. Vglut2
haploinsufficiency enhances behavioral sensitivity to MK-801 and amphetamine in
mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35, 1316–1321.
Niraula, A., Sheridan, J.F., Godbout, J.P., 2017. Microglia priming with aging and stress.
Neuropsychopharmacol. Rev. 42, 318–333.
Paradee, W., Melikian, H., Rasmussen, D., Kenneson, A., Conn, P., Warren, S., 1999.
Fragile X mouse: strain effects of knockout phenotype and evidence suggesting
deficient amygdala function. Neuroscience 94, 185–192.
Perry, V.H., Holmes, C., 2014. Microglial priming in neurodegenerative disease. Nat. Rev.
Neurol. 10, 217–224.
Petri, M., 2002. Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin.
Rheumatol. 16, 847–858.
Petri, M., Naqibuddin, M., Carson, K.A., Daniel, J., Weisman, M.H., Holliday, S.L.,
Padilla, P.A., Brey, R.L., 2010. Depression and cognitive impairment in newly
diagnosed systemic lupus erythematosus. J. Rheumatol. 37, 2032–2038.
Pikman, R., Kivity, S., Levy, Y., Arango, M.-T., Chapman, J., Yonath, H., Shoenfeld, Y.,
Gofrit, S., 2017. Neuropsychiatric SLE: from animal model to human. Lupus 26,
470–477.
Pisetsky, D.S., 2019. The Central Role of Nucleic Acids in the Pathogenesis of Systemic
Lupus Erythematosus. F1000 Res. 8 pii: F1000 Faculty Rev-368.
Rees, F., Doherty, M., Grainge, M.J., Lanyon, P., Zhang, W., 2017. The worldwide
incidence and prevalence of systemic lupus erythematosus: a systematic review of
epidemiological studies. Rheumatology 56, 1945–1961.
Rensing-ehl, A., Simon, V., Speckmann, C., Lorenz, M.R., Ritter, J., Janda, A., Abinun, M.,
Pircher, H., Bengsch, B., Thimme, R., Fuchs, I., Ammann, S., Allg, A., Huetker, S.,
Ingrid, K., Schwarz, K., Ehl, S., V€olkl, S., Speckmann, C., Lorenz, M.R., Ritter, J.,
Janda, A., Abinun, M., Pircher, H., Bengsch, B., Thimme, R., Fuchs, I., Ammann, S.,
Allg€auer, A., Kentouche, K., Cant, A., Hambleton, S., Bettoni de Cunha, C.,
Huetker, S., Kühnle, I., Pekrun, A., Seidel, M.G., Hummel, M., Mackensen, A.,
Schwarz, K., Ehl, S., 2014. Abnormally differentiated CD4þ or CD8þ T cells with
phenotypic and genetic features of double negative T cells in human Fas deficiency.
Blood 124, 851–861.
Ribeiro, F., Signorelli, F., 2017. The role of infections in neuropsychiatric lupus. Lupus 26,
490–496.
Rubtsov, A.V., Rubtsova, K., Kappler, J.W., Marrack, P., 2010. Genetic and hormonal
factors in female-biased autoimmunity. Autoimmun. Rev. 9, 494–498.
Rubtsova, K., Marrack, P., Rubtsov, A.V., 2015. Sexual dimorphism in autoimmunity.
J. Clin. Investig. 125, 2187–2193.
Schmittgen, T.D., Livak, K.J., 2008. Analyzing real-time PCR data by the comparative
C(T) method. Nat. Protoc. 3, 1101–1108.
Schwartz, N., Stock, A.D., Putterman, C., 2019. Neuropsychiatric lupus: new mechanistic
insights and future treatment directions. Nat. Rev. Rheumatol. 15, 137–152.
Shen, F., Hu, Z., Goswami, J., Gaffen, S.L., 2006. Identification of common transcriptional
regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281, 24138–24148.
Shimojima, Y., Matsuda, M., Gono, T., Ishii, W., Ikeda, S., 2005. Relationship between
clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus.
Clin. Rheumatol. 24, 469–475.
Skaug, B., Chen, J., Du, F., He, J., Ma, A., Chen, Z.J., 2011. Direct, noncatalytic
mechanism of IKK inhibition by A20. Mol. Cell 44, 559–571.
Stewart, C., Morris, R., 1993. The watermaze. Behav. Neurosci. 1, 107–122.
Stock, A.D., Wen, J., Doerner, J., Herlitz, L.C., Gulinello, M., Putterman, C., 2015.
Neuropsychiatric systemic lupus erythematosus persists despite attenuation of
systemic disease in MRL/lpr mice. J. Neuroinflammation 12.
Stock, A.D., Wen, J., Putterman, C., 2013. Neuropsychiatric lupus, the blood brain barrier,
and the TWEAK/Fn14 pathway. Front. Immunol. 4, 1–9.
Streit, W.J., Sammons, N.W., Kuhns, A.J., Sparks, L.D., 2004. Dystrophic microglia in the
aging human brain. Glia 45, 208–212.
Studer, P., Da Silva, C., Revuelta Cervantes, J., Mele, A., Csizmadia, E., Siracuse, J.,
Damrauer, S., Peterson, C., Candinas, D., Stroka, D., Ma, A., Bhasin, M., Ferran, C.,
2015. Significant lethality following liver resection in A20 heterozygous knockout
mice uncovers a key role for A20 in liver regeneration. Cell Death Differ. 22,
2068–2077.
Sweeney, M.D., Zhao, Zhen, Montagne, Axel, Nelson, A.R., Zlokovic, B.V., Zhao, Z.,
Montagne, A., Ar, N., Barrier, Z.B.V.B., 2019. Blood-Brain barrier: from physiology to
disease and back. Physiol. Rev. 99, 21–78.
Swerdlow, N.R., Weber, M., Qu, Y., Light, G.A., Braff, D.L., 2008. Realistic expectations of
prepulse inhibition in translational models for schizophrenia research.
Psychopharmacology (Berl) 199, 331–388.
van Dam, A., Wekking, E., Callewaert, J., Schipperijn, A., Oomen, H., de Jong, J.,
Swaak, A., Smeenk, R., Feltkamp, T., 1994. Psychiatric symptoms before systemic
lupus erythematosus is diagnosed. Rheumatol. Int. 14, 57–62.
Vendrell, J.A., Ghayad, S., Ben-Larbi, S., Dumontet, C., Mechti, N., Cohen, P.A., 2007.
A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in
breast cancer cells. Oncogene 26, 4656–4667.
C. Daems et al. Brain, Behavior, & Immunity - Health 2 (2020) 100018Vereecke, L., Sze, M., Mc Guire, C., Rogiers, B., Chu, Y., Schmidt-Supprian, M.,
Pasparakis, M., Beyaert, R., van Loo, G., 2010. Enterocyte-specific A20 deficiency
sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp.
Med. 207, 1513–1523.
Verhelst, K., Carpentier, I., Kreike, M., Meloni, L., Verstrepen, L., Kensche, T., Dikic, I.,
Beyaert, R., 2012. A20 inhibits LUBAC-mediated NF-kB activation by binding linear
polyubiquitin chains via its zinc finger 7. EMBO J. 31, 3845–3855.
Vincent, F.B., Northcott, M., Hoi, A., Mackay, F., Morand, E.F., 2013. Clinical associations
of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res. Ther. 15,
R97.
Voet, S., Mc Guire, C., Hagemeyer, N., Martens, A., Schroeder, A., Wieghofer, P.,
Daems, C., Staszewski, O., Vande Walle, L., Costa Jordao, M.J., Sze, M., Vikkula, H.,
Demeestere, D., Van Imschoot, G., Scott, C.L., Hoste, E., Gonçalves, A., Guilliams, M.,
Lippens, S., Libert, C., Vandenbroucke, R.E., Kim, K., Jung, S., Callaerts-vegh, Z.,
Callaerts, P., de Wit, J., Lamkanfi, M., Prinz, M., van Loo, G., 2018. A20 critically
controls microglia activation and inhibits inflammasome-dependent
neuroinflammation. Nat. Commun. 9, 2036.
Wang, S., Wen, F., Tessneer, K.L., Gaffney, P.M., 2016. TALEN-mediated enhancer
knockout in fluences TNFAIP3 gene expression and mimics a molecular phenotype
associated with systemic lupus erythematosus. Nat. Genet. 17, 165–170.
Wang, S., Wen, F., Wiley, G.B., Kinter, M.T., Gaffney, P.M., 2013. An enhancer element
harboring variants associated with systemic lupus erythematosus engages the
TNFAIP3 promoter to influence A20 expression. PLoS Genet. 9, e1003750.
Wang, X., Deckert, M., Xuan, N.T., Nishanth, G., Just, S., Waisman, A., Naumann, M.,
Schlüter, D., 2013. Astrocytic A20 ameliorates experimental autoimmune
encephalomyelitis by inhibiting NF-κB- and STAT1-dependent chemokine production
in astrocytes. Acta Neuropathol. 126, 711–724.
Watson, M.L., Rao, J.K., Gilkeson, G.S., Ruiz, P., Eicher, E.M., Pisetsky, D.S.,
Matsuzawa, A., Rochelle, J.M., Seldin, M.F., 1992. Genetic analysis of MRL/lpr mice:
relationship of the Fas apoptotis gene to disease manifestations and renal disease-
modifying loci. J. Exp. Med. 176, 1645–1656.
Wen, J., Doerner, J., Chalmers, S., Stock, A., Wang, H., Gullinello, M., Shlomchik, M.J.,
Putterman, C., 2016. B cell and/or autoantibody deficiency do not prevent
neuropsychiatric disease in murine systemic lupus erythematosus.
J. Neuroinflammation 13, 1–14.15Wertz, I.E., Newton, K., Seshasayee, D., Kusam, S., Lam, C., Zhang, J., Popovych, N.,
Helgason, E., Schoeffler, A., Jeet, S., Ramamoorthi, N., Kategaya, L., Newman, R.J.,
Horikawa, K., Dugger, D., Sandoval, W., Mukund, S., Zindal, A., Martin, F., Quan, C.,
Tom, J., Fairbrother, W.J., Townsend, M., Warming, S., Devoss, J., Liu, J., Dueber, E.,
Goodnow, C.C., Balazs, M., Yu, K., Kolumam, G., Dixit, V.M., 2015. Phosphorylation
and linear ubiquitin direct A20 inhibition of inflammation. Nature 528, 370–375.
Wertz, I.E., O’Rourke, K.M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P.,
Wiesmann, C., Baker, R., Boone, D.L., Ma, A., Koonin, E.V., Dixit, V.M., 2004. De-
ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kB signaling.
Nature 430, 694–699.
Willems, E., Leyns, L., Vandesompele, J., 2008. Standardization of real-time PCR gene
expression data from independent biological replicates. Anal. Biochem. 379,
127–129.
Yi Li, Y., Ming Li, X., 2000. The IAP family: endogenous caspase inhibitors with multiple
biological activities. Cell Res. 10, 169–177.
Zamanian, J.L., Xu, L., Foo, L.C., Nouri, N., Zhou, L.L., Giffard, R.G., Barres, B.A., 2012.
Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391–6410.
Zandman-Goddard, G., Solomon, M., Rosman, Z., Peeva, E., Shoenfeld, Y., 2012.
Environment and lupus-related diseases. Lupus 21, 241–250.
Zhang, Q., Lenardo, M.J., Baltimore, D., 2017. 30 Years of NF-κB: a blossoming of
relevance to human pathobiology. Cell 168, 37–57.
Zhang, Y., Chen, K., Sloan, S.A., Bennett, M.L., Scholze, A.R., O’Keeffe, S., Phatnani, H.P.,
Guarnieri, P., Caneda, C., Ruderisch, N., Deng, S., Liddelow, S.A., Zhang, C.,
Daneman, R., Maniatis, T., Barres, B.A., Wu, J.Q., 2014. An RNA-sequencing
transcriptome and splicing database of glia, neurons, and vascular cells of the
cerebral cortex. J. Neurosci. 34, 11929–11947.
Zhou, Q., Wang, H., Schwartz, D.M., Stoffels, M., Park, Y.H., Zhang, Y., Yang, D.,
Demirkaya, E., Takeuchi, M., Tsai, W.L., Lyons, J.J., Yu, X., Ouyang, C., Chen, C.,
Chin, D.T., Zaal, K., Chandrasekharappa, S.C., Hanson, E.P., Yu, Z., Mullikin, J.C.,
Hasni, S.A., Wertz, I.E., Ombrello, A.K., Stone, D.L., Hoffmann, P., Jones, A.,
Barham, B.K., Leavis, H.L., Royen-kerkof, A. Van, Sibley, C., Batu, E.D., Gül, A.,
Siegel, R.M., Boehm, M., Milner, J.D., Ozen, S., Gadina, M., Chae, J., Laxer, R.M.,
Kastner, D.L., Aksentijevich, I., 2015. Loss-of-function mutations in TNFAIP3 leading
to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat. Genet.
48, 67–73.
